Reinventing the vaccine clinical trial under modern scientific pressures

In Regulation and Policy by Freya SmaleLeave a Comment

download, vaccine clinical trials

Reinventing the vaccine clinical trial under modern scientific pressures

Dr David McIntosh, Global Scientific Affairs Senior Expert, Novartis Vaccines & Diagnostics joined us at the World Vaccine Congress in Washington 2012 to give his view on the changing nature of vaccine trials in light of modern scientific pressures.

The themes covered included:

  • New vaccines and their implications for clinical trials
  • Increased costs, globalisation, outsourcing, regulatory harmonisation, the rise of electronic data capture, clinical trial transparency and patient centricity
  • Harnessing new communication to increase efficiency an and speed of trials
  • What does the future hold for the current vaccine clinical trial model, and what solutions can be presented to ensure a successful ‘reinvention'?

 

Conclusions included:

  • Reverse vaccinology is a new technique for identifying targets
  • Meningococcal serogroup B vaccine promises to be the first vaccine invented in this way
  • Conjugate vaccines
  • Herd protection is an important added benefit  Healthcare associated infections
  • Staphylococcus aureus: considerable antigenic diversity and problem of MRSA
  • Maternal immunisation
  • Group B streptococcus (GBS) vaccine – new frontier

Download the full presentation here!

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *